Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease

Thorax

Volumn 63, Issue 6, 2008, Pages 549-554

  Holland, A E ^a,b,f   Hill, C J ^c,d   Conron, M ^e   Munro, P ^b   McDonald, C F ^c,d  

^a LA TROBE UNIVERSITY   (Australia)

^b BAYSIDE HEALTH   (Australia)

^c Institute for Breathing and Sleep   (Australia)

^d AUSTIN HEALTH   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSPNEA; EXERCISE; FIBROSING ALVEOLITIS; HEART RATE; HUMAN; INTERSTITIAL LUNG DISEASE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TELECONSULTATION; WALKING; WORKLOAD;

ADOLESCENT; ADULT; AGED; DYSPNEA; EXERCISE THERAPY; EXERCISE TOLERANCE; HUMANS; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; QUALITY OF LIFE; SOCIAL SUPPORT; TELEMEDICINE; TREATMENT OUTCOME;

EID: 45149130397     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2007.088070     Document Type: Article

References (38)

1. Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-42.
2. Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 2006;174:803-9.
3. Chang JA, Curtis JR, Patrick DL, et al. Assessment of health-related quality of life in patients with interstitial lung disease. Chest 1999;116:1175-82.
4. Lacasse Y, Goldstein R, Lasserson TJ, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006:CD003793.
5. Naji NA, Connor MC, Donnelly SC, et al. Effectiveness of pulmonary rehabilitation in restrictive lung disease. J Cardiopulm Rehabil 2006;26:237-43.
6. Foster S, Thomas HM 3rd. Pulmonary rehabilitation in lung disease other than chronic obstructive pulmonary disease. Am Rev Respir Dis 1990;141:601-4.
7. Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006;173:1390-413.
8. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:770-7.
9. Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med 1996;153:976-80.
10. Hansen JE, Wasserman K. Pathophysiology of activity limitation in patients with interstitial lung disease. Chest 1996;109:1566-76.
11. Harris-Eze AO, Sridhar G, Clemens RE, et al. Role of hypoxemia and pulmonary mechanics in exercise limitation in interstitial lung disease. Am J Respir Crit Care Med 1996;154:994-1001.
12. Chetta A, Aiello M, Foresi A, et al. Relationship between outcome measures of six-minute walk test and baseline lung function in patients with interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:170-5.
13. Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:1084-90.
14. Risk C, Epler GR, Gaensler EA. Exercise alveolar-arterial oxygen pressure difference in interstitial lung disease. Chest 1984;85:69-74.
15. Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006;129:746-52.
16. Bush A, Busst CM. Cardiovascular function at rest and on exercise in patients with cryptogenic fibrosing alveolitis. Thorax 1988;43:276-83.
17. Agusti AG, Roca J, Rodriguez-Roisin R, et al. Different patterns of gas exchange response to exercise in asbestosis and idiopathic pulmonary fibrosis. Eur Respir J 1988;1:510-16.
18. Wells AU, Hansell DM, Rubens MB, et al. Functional impairment in lone cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a comparison. Am J Respir Crit Care Med 1997;155:1657-64.
19. Idiopathic pulmonary fibrosis. Diagnosis and treatment. international consensus statement. Am J Respir Crit Care Med 2000;161:646-64.
20. ATS Statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-17.
21. Hallstrand TS, Boitano LJ, Johnson WC, et al. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J 2005;25:96-103.
22. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003;167:211-77.
23. Mahler D, Wells C. Evaluation of clinical methods for rating dyspnea. Chest 1988;93:580-6.
24. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-15.
25. Lachin JM. Statistical considerations in the intent-to-treat principle. Control Clin Trials 2000;21:167-89.
26. Miller ME, Morgan TM, Espeland MA, et al. Group comparisons involving missing data in clinical trials: a comparison of estimates and power (size) for some simple approaches. Stat Med 2001;20:2383-97.
27. Holland AE, Hill CJ, Nehez E, et al. Does unsupported upper limb exercise training improve symptoms and quality of life for patients with chronic obstructive pulmonary disease? J Cardiopulm Rehabil 2004;24:422-7.
28. Collard HR, Anstrom KJ, Schwarz MI, et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007;131:897-9.
29. Spruit MA, Thomeer MJ, Gosselink R, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005;60:32-8.
30. Nishiyama O, Taniguchi H, Kondoh Y, et al. Quadriceps weakness is related to exercise capacity in idiopathic pulmonary fibrosis. Chest 2005;127:2028-33.
31. Sala E, Roca J, Marrades RM, et al. Effects of endurance training on skeletal muscle bioenergetics in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159:1726-34.
32. Whittom F, Jobin J, Simard PM, et al. Histochemical and morphological characteristics of the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. Med Sci Sports Exerc 1998;30:1467-74.
33. Ries AL, Kaplan RM, Limberg TM, et al. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995;122:823-32.
34. Guell R, Casan P, Belda J, et al. Long-term effects of outpatient rehabilitation of COPD: A randomized trial. Chest 2000;117:976-83.
35. Foglio K, Bianchi L, Bruletti G, et al. Long-term effectiveness of pulmonary rehabilitation in patients with chronic airway obstruction. Eur Respir J 1999;13:125-32.
36. Johnson WC, Raghu G. Clinical trials in idiopathic pulmonary fibrosis: a word of caution concerning choice of outcome measures. Eur Respir J 2005;26:755-8.
37. Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest 2007;131:4S-42.
38. Swigris JJ, Kuschner WG, Kelsey JL, et al. Idiopathic pulmonary fibrosis: challenges and opportunities for the clinician and investigator. Chest 2005;127:275-83.